Advertisement

Investigation of mRNA Expression Levels of Tip60 and Related DNA Repair Genes in Molecular Subtypes of Breast Cancer

Published:November 11, 2022DOI:https://doi.org/10.1016/j.clbc.2022.10.012

      Abstract

      Introduction

      Studies in breast cancer (BC) have been shown that many tumor cells carry mutations that disrupt the DNA damage response mechanism. In eukaryotic cells, the overexpression or deprivation of DSBs repair genes is linked closely to a higher risk of cancer.

      Patients and Methods

      In this study, mRNA expression levels of some genes, such as Tip60, ATM, p53, CHK2, BRCA1, H2AX, which are associated with DNA damage repair, were measured using RT-PCR method in tumor and matched-normal tissues of 58 patients with BC.

      Results

      According to the study results, 55% in Tip60, 59% in ATM, 57% in BRCA1, 48% in H2AX, 66% in CHK2, and 43% in p53 decreased in tumor tissue of patients compared to the matched normal tissue. When evaluated according to molecular subtypes, expression of all genes in the pathway was found significantly higher in normal tissues than in tumor tissues especially in Luminal B and Luminal B+HER2 groups. One of the most important results of the study is that CHK2 mRNA expressions in normal tissues were higher than tumor tissue in 90% of patients in Luminal B and Luminal B-HER2 + groups. This is the first study showing DNA repair genes’ expressions in molecular subtypes of breast cancer. In general, the decrease in the expression of DNA damage repair genes in tumor tissue indicates that these genes may have a role in the development of BC. Our study results also suggest that CHK2 may be a candidate marker in the molecular classification of breast cancer

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H
        • Ferlay J
        • Siegel RL
        • et al.
        Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
        CA: A Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
        • Wolff AC
        • Hammond ME
        • Schwartz JN
        • et al.
        American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
        Arch Pathol Lab Med. 2007; 131 ([18:Asocco]2.0.Co;2): 18-43https://doi.org/10.1043/1543-2165(2007)131
        • Daniels MW
        • Brock GN
        • Wittliff JL.
        Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.
        Breast Cancer Res Treat. 2017; 161: 245-258https://doi.org/10.1007/s10549-016-4049-8
        • Fisher B
        • Redmond C
        • Brown A
        • et al.
        Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
        J Clin Oncol. 1983; 1: 227-241https://doi.org/10.1200/jco.1983.1.4.227
        • Perou CM
        • Sorlie T
        • Eisen MB
        • et al.
        Molecular portraits of human breast tumours.
        Nature. 2000; 406: 747-752https://doi.org/10.1038/35021093
        • Carey LA
        • Perou CM
        • Livasy CA
        • et al.
        Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
        J Am Med Assoc. 2006; 295: 2492-2502https://doi.org/10.1001/jama.295.21.2492
        • Goldhirsch A
        • Wood WC
        • Coates AS
        • et al.
        Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
        Ann Oncol. 2011; 22: 1736-1747https://doi.org/10.1093/annonc/mdr304
        • Elesawy BH
        • Abd El hafez A
        • Shawky Ael A
        • Arafa M
        Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients.
        Ann Diagn Pathol. 2014; 18: 21-26https://doi.org/10.1016/j.anndiagpath.2013.10.005
        • Zhang M
        • Liu HX
        • Teng XD
        • et al.
        The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer.
        Ultrastruct Pathol. 2012; 36: 381-386https://doi.org/10.3109/01913123.2012.728687
        • Irigaray P
        • Newby JA
        • Clapp R
        • et al.
        Lifestyle-related factors and environmental agents causing cancer: an overview.
        Biomedicine & Pharmacotherapy. 2007; 61: 640-658https://doi.org/10.1016/j.biopha.2007.10.006
        • Davis JD
        • Lin SY.
        DNA damage and breast cancer.
        World J Clin Oncol. 2011; 2: 329-338https://doi.org/10.5306/wjco.v2.i9.329
        • Rossetto D
        • Truman AW
        • Kron SJ
        • Cote J.
        Epigenetic modifications in double-strand break DNA damage signaling and repair.
        Clin Cancer Res. 2010; 16: 4543-4552https://doi.org/10.1158/1078-0432.CCR-10-0513
        • Sapountzi V
        • Logan IR
        • Robson CN.
        Cellular functions of TIP60.
        Int J Biochem & Cell Biology. 2006; 38: 1496-1509https://doi.org/10.1016/j.biocel.2006.03.003
        • Sun Y
        • Jiang X
        • Chen S
        • Fernandes N
        • Price BD.
        A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM.
        Proc Natl Acad Sci USA. 2005; 102: 13182-13187https://doi.org/10.1073/pnas.0504211102
        • Begam N
        • Jamil K
        • Raju SG.
        Promoter Hypermethylation of the ATM Gene as a Novel Biomarker for Breast Cancer.
        Asian Pac J Cancer Prev. 2017; 18: 3003-3009https://doi.org/10.22034/apjcp.2017.18.11.3003
        • Gyorffy B.
        Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer.
        Comput Struct Biotechnol J. 2021; 19: 4101-4109https://doi.org/10.1016/j.csbj.2021.07.014
        • Niida H
        • Katsuno Y
        • Sengoku M
        • Shimada M
        • Yukawa M
        • et al.
        Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase.
        Genes & Development. 2010; 24: 333-338https://doi.org/10.1101/gad.1863810
        • Squatrito M
        • Gorrini C
        • Amati B.
        Tip60 in DNA damage response and growth control: many tricks in one HAT.
        Trends Cell Biol. 2006; 16: 433-442https://doi.org/10.1016/j.tcb.2006.07.007
        • Bird AW
        • Yu DY
        • Pray-Grant MG
        • et al.
        Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair.
        Nature. 2002; 419: 411-415https://doi.org/10.1038/nature01035
        • Gorrini C
        • Squatrito M
        • Luise C
        • et al.
        Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.
        Nature. 2007; 448: 1063-1067https://doi.org/10.1038/nature06055
        • Halkidou K
        • Gnanapragasam VJ
        • Mehta PB
        • et al.
        Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development.
        Oncogene. 2003; 22: 2466-2477https://doi.org/10.1038/sj.onc.1206342
        • Murr R
        • Loizou JI
        • Yang YG
        • et al.
        Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks.
        Nat Cell Biol. 2006; 8: 91-99https://doi.org/10.1038/ncb1343
        • Sakuraba K
        • Yasuda T
        • Sakata M
        • et al.
        Down-regulation of Tip60 gene as a potential marker for the malignancy of colorectal cancer.
        Anticancer Res. 2009; 29: 3953-3955
        • Liu ZJ
        • Sun YL.
        Role of Tip60 tumor suppressor in DNA repair pathway.
        Chin Sci Bull. 2011; 56: 1212-1215https://doi.org/10.1007/s11434-011-4433-z
        • Tang Y
        • Luo J
        • Zhang W
        • Gu W.
        Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis.
        Mol Cell. 2006; 24: 827-839https://doi.org/10.1016/j.molcel.2006.11.021
        • Sun Y
        • Jiang X
        • Xu Y
        • et al.
        Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60.
        Nat Cell Biol. 2009; 11: 1376-1382https://doi.org/10.1038/ncb1982
        • Abdel-Fatah TM
        • Arora A
        • Alsubhi N
        • et al.
        Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
        Neoplasia. 2014; 16: 982-991https://doi.org/10.1016/j.neo.2014.09.009
        • Rondeau S
        • Vacher S
        • De Koning L
        • et al.
        ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.
        Br J Cancer. 2015; 112: 1059-1066https://doi.org/10.1038/bjc.2015.60
        • Bueno RC
        • Canevari RA
        • Villacis RA
        • et al.
        ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.
        Ann Oncol. 2014; 25: 69-75https://doi.org/10.1093/annonc/mdt421
        • Rondeau S
        • Vacher S
        • De Koning L
        • et al.
        ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.
        Br J Cancer. 2015; 112: 1059-1066https://doi.org/10.1038/bjc.2015.60
        • Kurebayashi J
        • Yamamoto Y
        • Kurosumi M
        • et al.
        Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with Taxanes.
        Anticancer Res. 2006; 26: 695-701
        • Al-Mulla F
        • Abdulrahman M
        • Varadharaj G
        • Akhter N
        • Anim JT.
        BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry.
        J Histochem Cytochem. 2005; 53: 621-629https://doi.org/10.1369/jhc.4A6544.2005
        • Rio PG
        • Maurizis JC
        • Peffault de Latour M
        • Bignon YJ
        • Bernard-Gallon DJ
        Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene.
        Int J Cancer. 1999; 80: 823-826https://doi.org/10.1002/(sici)1097-0215(19990315)80:6<823::aid-ijc5>3.0.co;2-3
        • Bassing CH
        • Suh H
        • Ferguson DO
        • et al.
        Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors.
        Cell. 2003; 114: 359-370https://doi.org/10.1016/s0092-8674(03)00566-x
        • Nagelkerke A
        • van Kuijk SJ
        • Martens JW
        • et al.
        Poor prognosis of constitutive γ-H2AX expressing triple-negative breast cancers is associated with telomere length.
        Biomark Med. 2015; 9: 383-390https://doi.org/10.2217/bmm.15.2
        • Nagelkerke A
        • van Kuijk SJ
        • Sweep FC
        • et al.
        Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.
        Radiother Oncol. 2011; 101: 39-45https://doi.org/10.1016/j.radonc.2011.07.009
        • Celeste A
        • Difilippantonio S
        • Difilippantonio MJ
        • et al.
        H2AX haploinsufficiency modifies genomic stability and tumor susceptibility.
        Cell. 2003; 114: 371-383https://doi.org/10.1016/s0092-8674(03)00567-1
        • Downs JA.
        Chromatin structure and DNA double-strand break responses in cancer progression and therapy.
        Oncogene. 2007; 26: 7765-7772https://doi.org/10.1038/sj.onc.1210874
        • Yoshida K
        • Morita T.
        Control of radiosensitivity of F9 mouse teratocarcinoma cells by regulation of histone H2AX gene expression using a tetracycline turn-off system.
        Cancer Res. 2004; 64: 4131-4136https://doi.org/10.1158/0008-5472.Can-03-2566
        • Taneja N
        • Davis M
        • Choy JS
        • et al.
        Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy.
        J Biol Chem. 2004; 279: 2273-2280https://doi.org/10.1074/jbc.M310030200
        • Vici P
        • Di Benedetto A
        • Ercolani C
        • et al.
        Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.
        Oncotarget. 2015; 6: 42773-42780https://doi.org/10.18632/oncotarget.6001
        • Zannini L
        • Delia D
        • Buscemi G.
        CHK2 kinase in the DNA damage response and beyond.
        J Mol Cell Biol. 2014; 6: 442-457https://doi.org/10.1093/jmcb/mju045
        • Jiang H
        • Reinhardt HC
        • Bartkova J
        • et al.
        The combined status of ATM and p53 link tumor development with therapeutic response.
        Genes & Development. 2009; 23: 1895-1909https://doi.org/10.1101/gad.1815309